摘要:
Provided herein are naphthylic derivative compounds, or pharmaceutically acceptable salts thereof, that are useful for inhibiting cancers. Also provided herein are methods of using effective amounts of said compounds, optionally with pharmaceutical carriers, for the treatment of cancers within human subjects.
摘要:
An antibody molecule or molecule containing antibody combining site portions (catalytic molecule) that catalytically hydrolyzes a preselected carboxylic acid amide or ester bond of a reactant ligand, methods of making and using the catalytic molecule, and cells that produce those molecules are disclosed. The catalytic molecules bind to a reactant ligand containing the bond to be hydrolyzed and also to a haptenic ligand. The haptenic ligand is structurally analogous to the reactant ligand and contains a tetrahedral carbon atom that is bonded to a hydroxyl group and to a saturated carbon atom at a position in the haptenic ligand that corresponds to position of the carbonyl group and its bonded heteroatom of the reactant ligand. The haptenic ligand also contains a group that bears an ionic charge in aqueous solution at physiological pH values that is not present at a corresponding position of the reactant ligand. The ionic charge-bearing group is located in the hapten within 7 .ANG.ngstroms of the tetrahedral carbon atom.
摘要:
Process for the manufacture of N-(2-halogenoethyl)-N-(2-hydroxy2-phenylethyl)amines, known intermediates in manufacture of the anthelmintic tetramisole. In one alternative, process comprises reacting N-(2-hydroxyethyl)-N-(2-hydroxy-2-phenylethyl)amine with a halogenating agent, e.g., thionyl chloride, to give N-(2halogenoethyl)-N-(2-halogeno-2-phenylethyl)amine salt, and reacting latter compound with water to give said monohalogeno compound. In another alternative, the isomeric N-(2hydroxyethyl)-N-(2-hydroxy-1-phenylethyl)amine is reacted with halogenating agent to give N-(2-halogenoethyl)-N-(2-halogeno-1phenylethyl)amine derivative, and reaction of latter with water gives said monohalogeno derivative. In another alternative, a mixture of the two said dihydroxy compounds is used as starting material. Conversion of the two dihalogeno derivatives to the same monohalogeno derivative proceeds, apart from exceptional circumstance, via an aziridine derivative.
摘要:
The present invention relates to a tandem process of reduction and host-guest complexation using metal-hydride complexes to reduce chemical entities bearing carbonyl groups or their equivalents, and host-guest complexation to achieve improved optical resolution of the reduction product. In the complexation step, the reduction product is optically resolved via inclusion into the crystalline complex where it resides as guest and another complex component acts as host. Additional crystallization stages are performed if further improvements in the enantiomeric excess is desired.
摘要:
A process is disclosed for the preparation of the substantially pure compound of the formula: ##STR1## comprising catalytic hydrogenation of a compound of the formula: ##STR2## wherein R.sub.6 and R.sub.7 are independently selected from ##STR3## wherein R.sub.a and R.sub.b are independently selected from hydrogen, loweralkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR4## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or R.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded are ##STR5## wherein R.sub.f, R.sub.g, R.sub.h and R.sub.i are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl; or an acid addition salt thereof.
摘要:
The invention relates to new phenylethanolamines of general formula ##STR1## wherein A represents a straight-chained or branched alkylene group,B represents a bond, an alkylene group, a carbonyl or hydroxymethylene group,R.sub.1 represents a hydrogen atom, a halogen atom or a trifluoromethyl group,R.sub.2 represents a hydrogen atom or an amino group,R.sub.3 represents a cyano group, a hydrogen, chlorine or bromine atom andR.sub.4 represents a hydrogen or halogen atom, an alkyl, hydroxy, alkoxy, carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl group or an alkoxy group substituted in the end position by a carboxy, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, hydroxy, alkoxy, amino, alkylamino, dialkylamino, pyrrolidino, piperidino or hexamethyleneimino group,the optical isomers and diastereoisomers and acid addition salts thereof.The new compounds of formula I, the optical isomers and diastereoisomers and acid addition salts thereof, particularly the physiologically acceptable acid addition salts thereof with inorganic or organic acids, have valuable pharmacological properties, namely an effect on the metabolism, preferably the effect of lowering blood sugar and reducing body fat and they may also be used as performance enhancers in animals.The new compounds of general formula I above may be prepared by methods known per se.
摘要:
This disclosure describes compounds of Formula I. ##STR1## (including their pharmaceutically acceptable salts and esters) which have potent antihistamine activity which are substantially free from sedative effects.
摘要:
A compound of the formula: ##STR1## wherein Z is ethyl or vinyl,R.sub.1 and R.sub.2 are hydrogen, lower alkyl, lower alkenyl or trihalomethyl,R.sub.3 and R.sub.4 are hydrogen, lower alkyl, lower alkenyl, trihalomethyl, cyclopentyl, benzyl or phenyl, andR.sub.5 is lower alkyl, lower alkenyl, trihalomethyl, cyclopentyl, benzyl, or phenyl with the proviso that where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 each is hydrogen, R.sub.5 is not methyl attached to the 4-position of the benzene ring, or a pharmaceutically acceptable acid addition or quaternary ammonium salt thereof is disclosed as effective in the regulation of the liver microsomal enzyme system.
摘要:
Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
摘要:
Compositions comprising (null)-2-((dimethylamino)methyl)cyclohexanone, a transition-metal salt, and an organic solvent and methods of preparing (null)-cis-2-((dimethylamino)methyl)-1-(aryl)cyclohexanols, in particular (null)-cis-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol, are disclosed herein. In one embodiment, the (null)-2-((dimethylamino)methyl)cyclohexanone and transition-metal salt are in the form of a (null)-2-((dimethylamino)methyl)cyclohexanone:transition-metal salt complex. In another embodimemt, aryl is 3-methoxyphenyl.